​

Quoin Pharmaceuticals (QNRX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

QNRX Stock Rating

Quoin Pharmaceuticals stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

QNRX Price Target Upside V Benchmarks

TypeNameUpside
StockQuoin Pharmaceuticals-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$8.47$8.47$8.47
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2511---2
May, 2511---2
Apr, 2511---2
Mar, 2511---2
Feb, 2511---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 15, 2024Maxim GroupBuyBuyhold

Financial Forecast

EPS Forecast

$-2K $-2K $-1K $-500 $0 $500 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-88.10$-9.64$-1.91K----
Avg Forecast$-162.00$-9.47$-2.08$-1.48$-0.05$1.15$1.34
High Forecast$-162.00$-8.55$-2.08$-1.48$-0.05$1.15$1.34
Low Forecast$-162.00$-10.39$-2.08$-1.48$-0.05$1.15$1.34
Surprise %-45.62%1.80%91799.04%----

Revenue Forecast

$10M $21M $32M $43M $54M $65M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast$3.75M--$15.58M$14.39M$48.51M$60.97M
High Forecast$3.75M--$15.58M$14.39M$48.51M$60.97M
Low Forecast$3.75M--$15.58M$14.39M$48.51M$60.97M
Surprise %-------

Net Income Forecast

$-9B $-7B $-5B $-3B $-1B $500M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.76M$-8.69M$-8.96B----
Avg Forecast$-145.98M$-8.69M$-1.87M$-1.33M$-45.05K$1.04M$1.21M
High Forecast$-145.98M$-7.70M$-1.87M$-1.33M$-45.05K$1.04M$1.21M
Low Forecast$-145.98M$-9.36M$-1.87M$-1.33M$-45.05K$1.04M$1.21M
Surprise %-98.79%-478080.09%----

QNRX Forecast FAQ

Is Quoin Pharmaceuticals stock a buy?

Quoin Pharmaceuticals stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Quoin Pharmaceuticals is a favorable investment for most analysts.

What is Quoin Pharmaceuticals's price target?

Quoin Pharmaceuticals's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $8.47.

How does Quoin Pharmaceuticals stock forecast compare to its benchmarks?

Quoin Pharmaceuticals's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Quoin Pharmaceuticals over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Quoin Pharmaceuticals’s EPS forecast?

Quoin Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.48, marking a -99.92% decrease from the reported $-1.912K in 2024. Estimates for the following years are $-0.05 in 2026, $1.15 in 2027, and $1.34 in 2028.

What is Quoin Pharmaceuticals’s revenue forecast?

Quoin Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $15.58M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $14.39M, followed by $48.51M for 2027, and $60.97M for 2028.

What is Quoin Pharmaceuticals’s net income forecast?

Quoin Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-1.331M, representing a -99.99% decrease from the reported $-8.962B in 2024. Projections indicate $-45.055K in 2026, $1.04M in 2027, and $1.21M in 2028.